PL3416654T3 - Medyczne zastosowanie adenozyno-5'-difosforanu rybozy (adpr) - Google Patents

Medyczne zastosowanie adenozyno-5'-difosforanu rybozy (adpr)

Info

Publication number: PL3416654T3
Authority: PL; Poland
Prior art keywords: fibosis; adpr; diphosphate; adenosine; medical uses
Prior art date: 2016-02-18

Application number

PL17708104T

Other languages

English (en)

Inventor

Robert Shalwitz

Original Assignee

Invirsa, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-18

Filing date

2017-02-17

Publication date

2022-03-21

2017-02-17 Application filed by Invirsa, Inc. filed Critical Invirsa, Inc.

2022-03-21 Publication of PL3416654T3 publication Critical patent/PL3416654T3/pl

Links

XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 title 1
PWJFNRJRHXWEPT-AOOZFPJJSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r)-2,3,4-trihydroxy-5-oxopentyl] hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O)[C@@H](O)[C@H]1O PWJFNRJRHXWEPT-AOOZFPJJSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Oncology (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Otolaryngology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL17708104T 2016-02-18 2017-02-17 Medyczne zastosowanie adenozyno-5'-difosforanu rybozy (adpr) PL3416654T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201662296665P	2016-02-18	2016-02-18
US201662428721P	2016-12-01	2016-12-01
EP17708104.9A EP3416654B1 (en)	2016-02-18	2017-02-17	Medical use of 5'-adenosine diphosphate ribose (adpr)
PCT/US2017/018253 WO2017143113A1 (en)	2016-02-18	2017-02-17	Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Publications (1)

Publication Number	Publication Date
PL3416654T3 true PL3416654T3 (pl)	2022-03-21

Family

ID=58191671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17708104T PL3416654T3 (pl)	2016-02-18	2017-02-17	Medyczne zastosowanie adenozyno-5'-difosforanu rybozy (adpr)

Country Status (16)

Country	Link
US (3)	US11110112B2 (pl)
EP (2)	EP3416654B1 (pl)
JP (4)	JP6946353B2 (pl)
KR (2)	KR102622656B1 (pl)
CN (2)	CN108601793B (pl)
AU (2)	AU2017219878B2 (pl)
BR (1)	BR112018016398A2 (pl)
DK (1)	DK3416654T3 (pl)
ES (1)	ES2900524T3 (pl)
HR (1)	HRP20211942T1 (pl)
HU (1)	HUE057052T2 (pl)
IL (2)	IL291574B2 (pl)
LT (1)	LT3416654T (pl)
PL (1)	PL3416654T3 (pl)
PT (1)	PT3416654T (pl)
WO (1)	WO2017143113A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108601793B (zh)	2016-02-18	2024-08-23	伊维萨股份有限公司	使用5′-腺苷二磷酸核糖(adpr)的方法
WO2019191026A2 (en)	2018-03-27	2019-10-03	Invirsa, Inc.	Methods for the use of 5'-adenosine diphosphate ribose (adpr)
KR102789553B1 (ko)	2021-09-07	2025-04-03	주식회사 펄스인마이어스	방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용
CN119278047A (zh) *	2023-03-02	2025-01-07	股份公司佛斯因迈尔斯	用于预防或治疗癌症的adp-核糖结合肽及adp-核糖的联合疗法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0618214A1 (en)	1993-04-01	1994-10-05	Merrell Dow Pharmaceuticals Inc.	Unsaturated phosphonate derivatives of purines and pyrimidines
JPH07247210A (ja)	1994-03-09	1995-09-26	Sunstar Inc	口腔用組成物
CA2302687A1 (en) *	1997-09-11	1999-03-18	Oxigene, Inc.	Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
JP2002537329A (ja)	1999-02-26	2002-11-05	インスパイアーファーマシューティカルズ，インコーポレイティド	特定のウリジン、アデニン及びシチジン二リン酸並びにそれらの類似体による粘膜水和の促進方法
KR20020026460A (ko)	1999-06-16	2002-04-10	게리 엘. 윌콕스	인체 폴리(ａｄｐ-리보스) 폴리메라제 2 물질 및 방법
US6528042B1 (en)	1999-10-08	2003-03-04	Galileo Laboratories, Inc.	Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US7115585B2 (en)	2000-08-21	2006-10-03	Inspire Pharmaceuticals, Inc.	Compositions for treating epithelial and retinal tissue diseases
EP1409503A1 (en)	2001-07-25	2004-04-21	Celltech R & D Limited	Non-natural carbon-linked nucleotides and dinucleotides
ATE417616T1 (de)	2002-05-21	2009-01-15	Abbott Lab	Behandlung von mukositis
US20070212395A1 (en)	2006-03-08	2007-09-13	Allergan, Inc.	Ocular therapy using sirtuin-activating agents
US20050276762A1 (en) *	2004-06-15	2005-12-15	Tapas Das	Topical compositions containing 5'-adenosine-diphosphate ribose
CA2609549A1 (en)	2005-05-25	2006-11-30	Sirtris Pharmaceuticals, Inc.	Treatment of eye disorders with sirtuin modulators
CA2629376C (en)	2005-11-14	2015-06-09	Centre National De La Recherche Scientifique - Cnrs	Inhibitors of parp activity and uses thereof
WO2008154129A1 (en)	2007-06-08	2008-12-18	Bausch & Lomb Incorporated	Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
US20110217262A1 (en)	2010-03-05	2011-09-08	Kornfield Julia A	Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
CA2798697A1 (en)	2010-05-10	2011-11-17	Radikal Therapeutics Inc.	Lipoic acid and nitroxide derivatives and uses thereof
TWI632914B (zh)	2011-05-12	2018-08-21	遠景生物製藥股份有限公司	具有類固醇類或非類固醇抗發炎藥之安定的普維酮－碘（Ｐｏｖｉｄｏｎｅ－Ｉｏｄｉｎｅ）組合物
WO2015073319A1 (en)	2013-11-18	2015-05-21	Massachusetts Institute Of Technology	Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction
CN108601793B (zh)	2016-02-18	2024-08-23	伊维萨股份有限公司	使用5′-腺苷二磷酸核糖(adpr)的方法
WO2019191026A2 (en)	2018-03-27	2019-10-03	Invirsa, Inc.	Methods for the use of 5'-adenosine diphosphate ribose (adpr)

2017
- 2017-02-17 CN CN201780011126.0A patent/CN108601793B/zh active Active
- 2017-02-17 KR KR1020187022959A patent/KR102622656B1/ko active Active
- 2017-02-17 HR HRP20211942TT patent/HRP20211942T1/hr unknown
- 2017-02-17 HU HUE17708104A patent/HUE057052T2/hu unknown
- 2017-02-17 EP EP17708104.9A patent/EP3416654B1/en active Active
- 2017-02-17 JP JP2018563379A patent/JP6946353B2/ja active Active
- 2017-02-17 US US15/999,269 patent/US11110112B2/en active Active
- 2017-02-17 CN CN202311353882.5A patent/CN117482102A/zh active Pending
- 2017-02-17 DK DK17708104.9T patent/DK3416654T3/da active
- 2017-02-17 KR KR1020237034890A patent/KR102883682B1/ko active Active
- 2017-02-17 EP EP21198288.9A patent/EP3978003A1/en not_active Withdrawn
- 2017-02-17 BR BR112018016398A patent/BR112018016398A2/pt not_active Application Discontinuation
- 2017-02-17 PL PL17708104T patent/PL3416654T3/pl unknown
- 2017-02-17 PT PT177081049T patent/PT3416654T/pt unknown
- 2017-02-17 WO PCT/US2017/018253 patent/WO2017143113A1/en not_active Ceased
- 2017-02-17 ES ES17708104T patent/ES2900524T3/es active Active
- 2017-02-17 IL IL291574A patent/IL291574B2/en unknown
- 2017-02-17 LT LTEPPCT/US2017/018253T patent/LT3416654T/lt unknown
- 2017-02-17 AU AU2017219878A patent/AU2017219878B2/en active Active
2018
- 2018-08-10 IL IL261095A patent/IL261095B/en unknown
2021
- 2021-08-03 US US17/392,578 patent/US11857561B2/en active Active
- 2021-09-15 JP JP2021149881A patent/JP7222042B2/ja active Active
2023
- 2023-02-02 JP JP2023014497A patent/JP7600282B2/ja active Active
- 2023-03-17 AU AU2023201678A patent/AU2023201678B2/en active Active
- 2023-11-07 US US18/503,967 patent/US12370209B2/en active Active
2024
- 2024-12-04 JP JP2024210859A patent/JP2025032189A/ja active Pending

Also Published As

Publication number	Publication date
IL261095B (en)	2022-04-01
WO2017143113A1 (en)	2017-08-24
US20220054522A1 (en)	2022-02-24
US11110112B2 (en)	2021-09-07
DK3416654T3 (da)	2021-12-13
IL291574A (en)	2022-05-01
EP3978003A1 (en)	2022-04-06
HRP20211942T1 (hr)	2022-03-18
KR102883682B1 (ko)	2025-11-10
CA3014071A1 (en)	2017-08-24
JP6946353B2 (ja)	2021-10-06
ES2900524T3 (es)	2022-03-17
EP3416654B1 (en)	2021-10-27
IL261095A (en)	2018-10-31
IL291574B2 (en)	2025-05-01
AU2017219878B2 (en)	2022-12-22
US20200330498A1 (en)	2020-10-22
AU2023201678B2 (en)	2025-03-13
AU2023201678A1 (en)	2023-04-13
PT3416654T (pt)	2021-12-22
JP2023055858A (ja)	2023-04-18
JP2021193126A (ja)	2021-12-23
EP3416654A1 (en)	2018-12-26
US12370209B2 (en)	2025-07-29
JP2019505596A (ja)	2019-02-28
KR20230148389A (ko)	2023-10-24
US20240091249A1 (en)	2024-03-21
CN108601793A (zh)	2018-09-28
AU2017219878A1 (en)	2018-08-09
CN117482102A (zh)	2024-02-02
JP2025032189A (ja)	2025-03-11
KR20180111841A (ko)	2018-10-11
JP7222042B2 (ja)	2023-02-14
HUE057052T2 (hu)	2022-04-28
IL291574B1 (en)	2025-01-01
BR112018016398A2 (pt)	2018-12-18
JP7600282B2 (ja)	2024-12-16
LT3416654T (lt)	2022-01-10
CN108601793B (zh)	2024-08-23
US11857561B2 (en)	2024-01-02
KR102622656B1 (ko)	2024-01-10

Publication	Publication Date	Title
IL284100A (en)	2021-07-29	N4-hydroxycytidine and derivatives and anti-viral uses related thereto
MA50172A (fr)	2021-04-07	Nucléosides substitués, nucléotides et analogues de ceux-ci
MA46180A (fr)	2021-03-24	Analogues de l'amyline
EP3277381C0 (en)	2026-01-07	Nitrobenzene derivatives of anticancer drugs
EP3464313A4 (en)	2020-02-26	MODIFIED NUCLEOTIDES 5 '-CYCLO-PHOSPHONATE
LT3265102T (lt)	2025-10-27	Beta-d-2'-deoksi-2'alfa-fluor-2'-beta-c-pakeistieji-2-modifikuoti-n6- pakeistieji purino nukleotidai, skirti hcv gydymui
EP3294212A4 (en)	2019-02-27	DRUG DELIVERY FROM HYDROGEL
EP3431075A4 (en)	2020-01-22	EDARAVONDARREICHUNGSFORM
EP3265180A4 (en)	2019-04-24	HUMAN FIBROLAMELLAR Liver Cell Carcinomas (HFL-HCCS)
EP3250367A4 (en)	2019-01-09	ACTIVE CALIBRATION
HUE071358T2 (hu)	2025-08-28	Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk
EP3331430A4 (en)	2019-03-20	DEVICES AND METHOD FOR MAPPING HERZARRYTHMIES
FR3056393B1 (fr)	2018-10-12	Orthese d'extension de machoires
EP3416647A4 (en)	2019-10-23	N3-SUBSTITUTED IMINOPYRIMIDINONE AS ANTIMALARIAMIDAL
EP3347334A4 (en)	2019-05-01	DEHYDROHALOGENICATION OF FLUOROCHOLE HYDROGEN
LT3463351T (lt)	2022-06-10	Parkinsono ligos gydymas
EP3658683A4 (en)	2021-04-21	TROGOCYTOSIS-MEDIATED EPITOPE DISCOVERY
EP3472176A4 (en)	2020-02-26	USE OF (+) EPICATECHIN AND ITS ANALOG
EP3638230A4 (en)	2021-04-21	Antiviral drugs
PL3416654T3 (pl)	2022-03-21	Medyczne zastosowanie adenozyno-5'-difosforanu rybozy (adpr)
EP3815657A4 (en)	2022-03-23	WEARABLE DISPOSABLE
EP3448392A4 (en)	2020-01-15	ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
EP3440041A4 (en)	2019-10-23	SYNTHESIS OF 2'-FLUORO-6'-METHYLENE-CARBOCYCLIC ADENOSINE (FMCA) AND 2'-FLUORO-6'-METHYLENE-CARBOCYCLIC GUANOSINE (FMCG)
EP3407974A4 (en)	2019-08-28	Amlexanox Analogs
IL263155A (en)	2018-12-31	Combination formulation of three antiviral compounds